Skip to main content
SpringerLink
Log in

Cetuximab and panitumumab cost effective for mCRC

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. folinic acid, fluorouracil and oxaliplatin

  2. folinic acid, fluorouracil and irinotecan

  3. 2015/2016 British pounds

Reference

  • Tikhonova IA, et al. Economic Analysis of First-Line Treatment with Cetuximab or Panitumumab for RAS Wild-Type Metastatic Colorectal Cancer in England. PharmacoEconomics : 1 Mar 2018. Available from: URL: https://doi.org/10.1007/s40273-018-0630-9

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Cetuximab and panitumumab cost effective for mCRC. PharmacoEcon Outcomes News 798, 8 (2018). https://doi.org/10.1007/s40274-018-4755-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-018-4755-z

Search

Navigation